Delaware
|
001-34079
|
11-3516358
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
15245 Shady Grove Road, Suite 455
Rockville, MD
|
20850
|
|
(Address of principal executive offices)
|
(Zip Code)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $.0001 par value
|
REXN
|
Nasdaq Capital Market
|
Item 1.01 |
Entry into Material Definitive Agreement.
|
Item 3.02 |
Unregistered Sales of Equity Securities.
|
Item 9.01 |
Financing Statements and Exhibits.
|
(d) |
Exhibits.
|
Exhibit
No.
|
Description
|
|
Warrant Exchange Agreement, dated September 1, 2020, by and between Rexahn Pharmaceuticals, Inc. and Anson Investments Master Fund LP.
|
||
*
|
Portions of this exhibit have been omitted in compliance with Item 601 of Regulation S-K.
|
REXAHN PHARMACEUTICALS, INC.
|
|
Date: September 2, 2020
|
/s/ Douglas J. Swirsky
|
Douglas J. Swirsky
|
|
President and Chief Executive Officer
|